<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504491</url>
  </required_header>
  <id_info>
    <org_study_id>GELLC-2</org_study_id>
    <secondary_id>2007-003097-26</secondary_id>
    <nct_id>NCT00504491</nct_id>
  </id_info>
  <brief_title>R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia</brief_title>
  <acronym>R-CHOP</acronym>
  <official_title>Rescue Treatment With Rituximab-CHOP Therapy and Alemtuzumab (R-CHOP-A) in Refractory or Recidivant Patients With Chronic Lymphocytic Leukemia After Purine-analogous Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CABYC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Francesc Bosch, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CABYC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since there is no standard rescue therapy for refractory CLL or relapsed to the purine
      analogous, our target is to carry out a rescue therapy combining several chemotherapy agents
      (CHOP) adding the synergistic effect of Rituximab in order to act against tumour-like CLL
      forms, with assessable size lymph nodes. Afterwards, based in other studies, we shall study
      the role of Alemtuzumab as drug for consolidation or improvement of responses obtained with
      the initial therapy (CHOP-R), acting by &quot;cleaning&quot; from peripheral blood and bone marrow the
      CLL lymphocytes that may have had remain as residual after chemotherapy induction therapy.
      More precisely, the addition of Alemtuzumab as maintenance treatment would increase the
      complete responses with negative residual disease number and may prolong the duration of the
      response. For this, it is necessary to have not only an adequate and rigorous clinical
      follow-up but also biological, i.e. being able to analyze minimal residual disease by
      molecular biology techniques. This is the reason of writing this phase II clinical trial
      protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES

      The objectives of this clinical trial are the following:

        -  Main objective of the study: Overall response rate obtained after R-CHOP regime followed
           by Alemtuzumab consolidation as second line therapy

        -  Secondary objectives

             -  Determine the molecular complete response rate after R-CHOP regimen

             -  Determine the efficacy of Alemtuzumab in response improvement after R-CHOP regimen:
                conversion of PR to CR and of MRD+ to MRD-.

             -  Applicability (toxicity profile) of Alemtuzumab consolidation therapy.

             -  As additional objectives will be considered:

                  1. Prognostic value of several biological variables (ZAP-70 and cytogenetics)
                     having influence on the response

                  2. Response duration

                  3. Progression free survival

                  4. Overall survival
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IMP new owner decision
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate obtained after R-CHOP regimen followed by consolidation therapy with Alemtuzumab, as second line therapy. Haematological and non haematological toxicity will be graded in accordance with the WHO system</measure>
    <time_frame>57 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <condition>Patients Resistant to a Purine Analogous</condition>
  <condition>Patients Relapsed With Purines Therapy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5
(**) 1st course, 375 mg/m2 (*) If lymphocyte count is &gt; 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab-CHOP-Alemtuzumab</intervention_name>
    <description>Four Rituximab - CHOP courses will be given The courses will be given every 21 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient's written informed consent before initiation of any specific procedure related
             with the study.

          2. Age ≥ 18 years and ≤ 70 years

          3. (ECOG) ≤ 2

          4. Patients suffering from chronic lymphocyte leukaemia according to the established
             diagnostic criteria (Addendum A).

          5. Active CLL defined by the presence of one or more of the following criteria:

               -  Related symptoms: weight loss &gt;10% in the 6 previous months, or fever &gt;38ºC for 2
                  weeks with no evidence of infections, or extreme fatigue, or night sweats with no
                  evidence of infection.

               -  5.2.Enlarged lymph nodes or giant node clusters (&gt;10 cm in diameter) or
                  progressive growth lymph nodes.

               -  5.3.Giant splenomegaly (&gt; 6 cm under ribs border) or progressive splenomegaly.

               -  5.4.Progressive lymphocytosis (&gt;50% increase in a period of 2 months) or
                  lymphocyte duplication time (expected) &lt; 6 months

               -  5.5.Proof of progressive bone marrow failure evidenced by development or
                  worsening of anaemia and/or thrombopenia.

          6. Patients previously treated in first line with purine analogous and showing:

               -  Treatment failure (stable disease or progression)

               -  Relapse within three years of therapy.

          7. Agreement to use a high efficacy contraception method throughout all study period.

        Exclusion Criteria:

          1. Age &gt; 70 years

          2. Patients having received more than one therapy line

          3. Patients that had not received previously purine analogous therapy.

          4. CLL patients in transformation to more aggressive cytologic or pathologic forms
             (Pro-lymphocytic leukaemia large cell lymphoma, Hodgkin's lymphoma)

          5. Hypersensitivity shown as anaphylactic reaction to any of the DRUGS used in the trial.

          6. Patients with severe heart, lung, neurological, psychiatric or metabolic diseases not
             due to CLL

          7. Patients under systemic and continued steroid therapy.

          8. Impairment of renal function (Creatinine &gt; 2 times the upper limit of normal)
             non-attributable to CLL.

          9. Patients suffering anaemia or thrombocytopenia of autoimmune origin as well as those
             with a positive Coombs test

         10. Impairment of liver function (Bilirubin, ASAT/ALAT or Gamma-GT &gt; 2 times upper limit
             of normal) non attributable to CLL

         11. Patients with active severe infectious disease

         12. Patients suffering another malignancy (with the exception of focalized skin carcinoma)

         13. Patients with positive serum tests for HBsAg or CHV

         14. Patients with history of HIV or other severe immune depression conditions.

         15. Pregnant or breast feeding women

         16. Patients unable to attend the controls under outpatient regimen

         17. Patients previously treated with alemtuzumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesc Bosch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Althaia</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacion Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial.</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Gran Canaria</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Francisco de Borja</name>
      <address>
        <city>Gandia</city>
        <state>Valencia</state>
        <zip>46700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valle de Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Gerona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D.Anderson Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>36680</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46018</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>December 28, 2011</last_update_submitted>
  <last_update_submitted_qc>December 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rituximab-CHOP</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Chronic lymphocytic leukaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

